中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
24期
113-113,114
,共2页
中药%膝骨性关节炎%白细胞介素1%肿瘤坏死因子-α
中藥%膝骨性關節炎%白細胞介素1%腫瘤壞死因子-α
중약%슬골성관절염%백세포개소1%종류배사인자-α
traditional Chinese medicine%knee osteoarthritis%IL-1%TNF-α
目的:探讨中药内服外敷对膝骨性关节炎(KOA)患者血清白细胞介素-1( IL-1)及肿瘤坏死因子-α( TNF-α)水平的影响。方法观察并记录168例KOA患者在服用滋补肝肾活血通络方及外敷膝痛外敷方治疗前、治疗后3 d、1周、2周、4周血清IL-1、TNF-α水平及疼痛视觉模拟评分(VAS)。结果 KOA患者VAS、IL-1及TNF-α在治疗后3 d较治疗前下降不明显,在治疗后1周较治疗前显著下降( P﹤0.05),治疗后2周及4周时下降更显著( P﹤0.01)。结论中药内服外敷可缓解KOA患者疼痛,且能降低血清IL-1及TNF-α水平,适合KOA患者的长期治疗。
目的:探討中藥內服外敷對膝骨性關節炎(KOA)患者血清白細胞介素-1( IL-1)及腫瘤壞死因子-α( TNF-α)水平的影響。方法觀察併記錄168例KOA患者在服用滋補肝腎活血通絡方及外敷膝痛外敷方治療前、治療後3 d、1週、2週、4週血清IL-1、TNF-α水平及疼痛視覺模擬評分(VAS)。結果 KOA患者VAS、IL-1及TNF-α在治療後3 d較治療前下降不明顯,在治療後1週較治療前顯著下降( P﹤0.05),治療後2週及4週時下降更顯著( P﹤0.01)。結論中藥內服外敷可緩解KOA患者疼痛,且能降低血清IL-1及TNF-α水平,適閤KOA患者的長期治療。
목적:탐토중약내복외부대슬골성관절염(KOA)환자혈청백세포개소-1( IL-1)급종류배사인자-α( TNF-α)수평적영향。방법관찰병기록168례KOA환자재복용자보간신활혈통락방급외부슬통외부방치료전、치료후3 d、1주、2주、4주혈청IL-1、TNF-α수평급동통시각모의평분(VAS)。결과 KOA환자VAS、IL-1급TNF-α재치료후3 d교치료전하강불명현,재치료후1주교치료전현저하강( P﹤0.05),치료후2주급4주시하강경현저( P﹤0.01)。결론중약내복외부가완해KOA환자동통,차능강저혈청IL-1급TNF-α수평,괄합KOA환자적장기치료。
Objective To explore the effects of oral and external application of traditional Chinese medicines on the serum levels of IL-1 and TNF-α in the patients with knee osteoarthritis(KOA). Methods The Visual Analogue Scale(VAS)scores and serum levels of IL-1 and TNF-α were observed in 168 patients with KOA before the treatment of oral prescription for nourishing liver and kid-ney,and promoting blood circulation to remove meridian obstruction,and the external application of the gonalgia external application pre-scription and on 3 d,at 1,2,4 weeks after treatment. Results The VAS scores and serum levels of IL-1 and TNF-α on 3 d after treatment did not decreased obviously,but which were significantly decreased after 1-week treatment( P ﹤ 0. 05)and more significantly decreased after 2-week and 4-week treatment( P ﹤ 0. 01). Conclusion Oral and external application of traditional Chinese medicines relieves the pain of KOA and simultaneously decreases the serum levels of IL-1 and TNF-α,which is suitable for the long term treatment of the KOA patients.